Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Debt (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Total Debt for 8 consecutive years, with $3.5 million as the latest value for Q4 2022.

  • Quarterly Total Debt fell 77.52% to $3.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2022, down 77.52% year-over-year, with the annual reading at $3.5 million for FY2022, 77.52% down from the prior year.
  • Total Debt hit $3.5 million in Q4 2022 for Aptevo Therapeutics, down from $3.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $25.2 million in Q3 2020 to a low of $3.5 million in Q4 2022.
  • Historically, Total Debt has averaged $15.7 million across 5 years, with a median of $19.2 million in 2018.
  • Biggest five-year swings in Total Debt: increased 27.87% in 2020 and later crashed 77.52% in 2022.
  • Year by year, Total Debt stood at $19.3 million in 2018, then increased by 3.03% to $19.9 million in 2019, then increased by 26.13% to $25.1 million in 2020, then plummeted by 38.64% to $15.4 million in 2021, then plummeted by 77.52% to $3.5 million in 2022.
  • Business Quant data shows Total Debt for APVO at $3.5 million in Q4 2022, $3.9 million in Q3 2022, and $4.4 million in Q2 2022.